Evidence map›Paper›PMID 32790768›Full record

ArticlePloS one2020

Integrated system for detection and molecular characterization of circulating tumor cells.

Yusuke Takahashi, Kentaro Shirai, Yuichi Ijiri, Eri Morita, Tomokazu Yoshida, Shigeki Iwanaga, Masatoshi Yanagida

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yusuke TakahashiDepartment of Central Research Laboratories, Sysmex Corporation, Takatsukadai, Nishi-ku, Kobe, Japan.ORCID 0000-0001-8835-6295
Kentaro ShiraiDepartment of Central Research Laboratories, Sysmex Corporation, Takatsukadai, Nishi-ku, Kobe, Japan.
Yuichi IjiriDepartment of Central Research Laboratories, Sysmex Corporation, Takatsukadai, Nishi-ku, Kobe, Japan.
Eri MoritaDepartment of Central Research Laboratories, Sysmex Corporation, Takatsukadai, Nishi-ku, Kobe, Japan.ORCID 0000-0002-4876-9009
Tomokazu YoshidaDepartment of Central Research Laboratories, Sysmex Corporation, Takatsukadai, Nishi-ku, Kobe, Japan.
Shigeki IwanagaDepartment of Central Research Laboratories, Sysmex Corporation, Takatsukadai, Nishi-ku, Kobe, Japan.
Masatoshi YanagidaDepartment of Central Research Laboratories, Sysmex Corporation, Takatsukadai, Nishi-ku, Kobe, Japan.
Sysmex (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circulating tumor cells (CTCs) invade blood vessels in solid tumors and promote metastases by circulating in the blood. CTCs are thus recognized as targets for liquid biopsy and can provide useful information for design of treatments. This diagnostic approach must consider not only the number of CTCs but also their molecular and genetic characteristics. For this purpose, use of devices that enrich CTCs independent of these characteristics and detectors that recognize various CTC characteristics is essential. In the present study, we developed a CTC detection system comprising ClearCell FX and ImageStream Mark II. We clarified the analytical performance of this system by evaluating recovery rate, lower limits of detection, and linearity. These parameters are critical for detecting rare cells, such as CTCs. We tested these parameters using three cell lines with different expression levels of the epithelial marker-epithelial cell adhesion molecule (EpCAM) and spiked these cells into whole-blood samples from healthy donors. The average recovery rate and lower limit of detection were approximately 40% and five cells/7.5 mL of whole blood, respectively. High linearity was observed for all evaluated samples. We also evaluated the ability of the system to distinguish between normal and abnormal cells based on protein expression levels and gene amplification and found that the system can identify abnormal cells using these characteristics. The CTC detection system thus displays the ability to distinguish specific characteristics of CTC, thereby providing valuable information for cancer treatment.

Indexed as

Biomarkers, TumorEpithelial Cell Adhesion MoleculeHumansNeoplasmsNeoplastic Cells, CirculatingTumor Cells, CulturedBiomarkers, TumorEPCAM protein, humanEpithelial Cell Adhesion Molecule

Identifiers

PMID32790768
PMCPMC7425940
OpenAlexW3048909610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.